Dr. Carter will give a talk about bioindustry development cycles and introducing the challenges and opportunities for all early-stage companies.

Mr. Grady will address why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas so far and what can we expect from these strategies?

Dr. Li is a Venture Partner with Lilly Asia Ventures. He was most recently Executive VP and Global Head of Business Development at BeiGene; prior to that, he was VP of Business Development and Licensing at Merck and Executive Director of External R&D at Amgen. With over 21 years of industry experience, he will be sharing his investment strategy and insights.

Dr. McCracken will share his insight regarding Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients.